Abstract

.Lymphatic filariasis (LF) is endemic in 72 countries; 15 million persons live with chronic filarial lymphedema. It can be a disabling condition, frequently painful, leading to reduced mobility, social exclusion, and depression. The Global Program to Eliminate Lymphatic Filariasis aims to stop new infections and care for affected persons, but morbidity management has been initiated in only 38 countries. We examine economic costs and benefits of alleviating chronic lymphedema and its effects through simple limb care. We use economic and epidemiological data from 12 Indian states in which 99% of Indians with filariasis reside. Using census data, we calculate the age distribution of filarial lymphedema and predict the burden of morbidity of infected persons. We estimate lifetime medical costs and lost earnings due to lymphedema and acute dermatolymphangioadenitis (ADLA) with and without community-based limb-care programs. Programs of community-based limb care in all Indian endemic areas would reduce costs of disability by 52%, saving a per person average of US$2,721, equivalent to 703 workdays. Per-person savings are 185 times the program’s per-person cost. Chronic lymphedema and ADLA impose a substantial physical and economic burden in filariasis-endemic areas. Low-cost programs for lymphedema management based on limb washing and topical medication are effective in reducing the number of ADLA episodes and stopping progression of disabling lymphedema. With reduced disability, people can work longer hours per day, more days per year, and in more strenuous, higher paying jobs, resulting in important economic benefits to themselves, their families, and their communities.

Highlights

  • Lymphatic filariasis (LF) afflicts an estimated 120 million people in 72 countries of Africa, Asia, Oceania, and the Americas and is one of the diseases targeted for elimination by the World Health Assembly (World Health Assembly Resolution 50.29, 1997).[1,2,3,4] India is the country with the largest number of infected persons, accounting for 42% of the global endemic population.[2]

  • We identified 15,853 persons in the Khurda census with lower limb filarial lymphedema and derived the age distribution of morbidity due to lymphedema and acute dermatolymphangioadenitis (ADLA) episodes

  • This study found that the lifetime present value of the benefit of community-based lymphedema management was US$2,721 per participant

Read more

Summary

Introduction

Lymphatic filariasis (LF) afflicts an estimated 120 million people in 72 countries of Africa, Asia, Oceania, and the Americas and is one of the diseases targeted for elimination by the World Health Assembly (World Health Assembly Resolution 50.29, 1997).[1,2,3,4] India is the country with the largest number of infected persons, accounting for 42% of the global endemic population.[2]. An estimated 40 million people live with the disabling effects of LF, including about 15 million persons with chronic filarial lymphedema, primarily of the legs, and of the arms, breasts, and scrotum, and 25 million men with hydrocele.[1,4] Asymptomatic LF-infected persons are at life-long risk of

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call